Feraheme (ferumoxytol) Injection

Important Safety Information | Full Prescribing Information

Feraheme® (ferumoxytol) Injection for intravenous (IV) use is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.

Feraheme is contraindicated in patients with known hypersensitivity to Feraheme or any of its components.

This website is intended for US Healthcare Professionals only.

AMAG Pharmaceuticals

Terms of Use

This Web Site is owned by AMAG Pharmaceuticals, Inc. Lexington, Massachusetts, USA (“AMAG”) and operated either by us or by a third party with whom we have contracted to host this Web Site for us. The information provided on this Web Site is for general informational and educational purposes only.

AMAG Pharmaceuticals, Inc. Terms of Use Agreement (the “Agreement”)

Terms of Use Agreement

EFFECTIVE AS OF June 3, 2013

Welcome to the AMAG Pharmaceuticals Web Site. The AMAG World Wide Web Site WWW.AMAGPHARMA.COM Web Site, or any of our Web Sites, including without limitation WWW.FERAHEME.COM, WWW.IRONMATTERS.COM, and WWW.IDANEMIA.COM (the “Site” or “Web Site”), is a copyrighted work belonging to AMAG Pharmaceuticals, Inc. This Web Site is owned and operated by AMAG Pharmaceuticals, Inc. (“AMAG”), Lexington, Massachusetts, USA. PLEASE READ THESE TERMS OF USE CAREFULLY. BY ACCESSING THE SITE, YOU AGREE TO BE BOUND BY THE TERMS OF USE. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS OF USE, YOU MAY NOT ACCESS OR USE THIS SITE.

The information provided on this Web Site is for general informational and educational purposes only. The information provided on this Site is intended for the use of residents of the United States only.

Copyright © 2004-2012 AMAG Pharmaceuticals, Inc. All rights reserved.

Important Safety Information for Feraheme (Ferumoxytol) Injection

Indication and contraindication

Warnings and precautions

Adverse reactions

Post-marketing safety experience